Microbiotica Raises €42 Mn in Series C Funding to Advance Ulcerative Colitis Treatment

Microbiotica is developing new medicines that can be taken by mouth. These treatments use the human microbiome, which includes the microorganisms living in and on the body, to help treat diseases.

The funding round was led by British Business Bank. Other investors included Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest and Seventure Partners. All investors from the company's previous Series B round also participated in the latest funding.

Tim Sharpington, Chief Executive Officer of Microbiotica, says: “This financing marks an important next stage for Microbiotica and reflects the significant progress we have made in translating our powerful genomics-driven microbiome platform into clinical-stage products, alongside developing a scalable and cost-effective manufacturing process. We are thankful for the support received from our investors and are now focused on taking MB310 into Phase 2 clinical development, where we have an opportunity to further establish MB310 as a breakthrough treatment option for people living with ulcerative colitis.”

Carmine Circelli, Senior Investment Director, Life Sciences at the British Business Bank, adds: “We believe Microbiotica is emerging as a world leader in the development of microbiome therapeutics. Its Phase 1b study in ulcerative colitis produced statistically significant clinical remission, best in disease potential with no safety issues. This funding allows the Company to move MB310 forward into a Phase 2 trial which, if it confirms the promise seen in Phase 1b, has the potential to be a major breakthrough in the treatment of ulcerative colitis."

Dr Sam Williams, Venture Partner at IP Group, says: “We have been very impressed by Microbiotica’s progress since we first invested in the Company, from translating pioneering microbiome science from the Wellcome Sanger Institute into a powerful genomics-driven microbiome platform that has generated promising efficacy in two Phase 1b clinical trials. There is an important opportunity to advance Microbiotica’s precision microbiome approach into a larger clinical study, and we are pleased to continue supporting the Company as it enters this next phase of development.”

Founded in 2016, Microbiotica started as a spinout from the Wellcome Sanger Institute. The company develops medicines based on the human microbiome, which includes the microorganisms living in the body.

Microbiotica uses genetic research and advanced technology to study the human microbiome. Its platform combines a large collection of bacteria with a specialised genome database, bioinformatics and machine learning tools.

By studying clinical trial data, the company can identify bacteria linked to better treatment outcomes in specific groups of patients. This research could help scientists develop more targeted treatments.

Microbiotica has established partnerships with several organisations to support its research and development. These include MSD, Cancer Research UK, Genentech, the University of Adelaide and Cambridge University Hospitals NHS Foundation Trust.

Read Also- Unravel Health Raises €2.96 Mn to Develop At-Home Hormone Testing Device